Analyst Rami Katkhuda from LifeSci Capital maintained a Buy rating on Viridian Therapeutics (VRDN – Research Report) and keeping the price target at $46.00. Discover outperforming stocks and ...
Thomas Smith’s rating is based on the promising developments and strategic positioning of Viridian Therapeutics. The company has reported favorable Phase 3 results for its lead asset ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback